SBIO ALPS Medical Breakthroughs ETF $33.92
As of 1:00:00 AM EDT | 2/15/19 | Market Closed
SBIO Trading Data Previous Last Price $33.25
Volume Monthly Avg. Volume 50,055
Quarterly Avg. Volume 75,893
SBIO Fund Description The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
SBIO Summary Tracks This Index ALPS Medical Breakthroughs ETF
Asset Class Portfolio-Multi Asset
Asset Class Size Healthcare
SBIO Holdings Top 10 Holdings Cash and Equivalents
674%
Array BioPharma Inc. (
ARRY )
576%
United Therapeutics Corp. (
UTHR )
444%
Agios Pharmaceuticals Inc. (
AGIO )
403%
Emergent BioSolutions Inc. (
EBS )
394%
Ascendis Pharma AS (
ASND )
361%
Global Blood Therapeutics Inc. (
GBT )
338%
Total SBIO Holdings Total Holdings: 72 Cash and Equivalents
674%
Array BioPharma Inc. (
ARRY )
576%
United Therapeutics Corp. (
UTHR )
444%
Agios Pharmaceuticals Inc. (
AGIO )
403%
Emergent BioSolutions Inc. (
EBS )
394%
Ascendis Pharma AS (
ASND )
361%
Global Blood Therapeutics Inc. (
GBT )
338%
Ligand Pharmaceuticals Inc. (
LGND )
301%
Arena Pharmaceuticals Inc. (
ARNA )
288%
Halozyme Therapeutics Inc. (
HALO )
288%
Mirati Therapeutics Inc. (
MRTX )
276%
Madrigal Pharmaceuticals Inc. (
MDGL )
243%
Enanta Pharmaceuticals Inc. (
ENTA )
234%
Acceleron Pharma Inc. (
XLRN )
230%
Atara Biotherapeutics Inc. (
ATRA )
216%
CRISPR Therapeutics AG (
CRSP )
189%
PTC Therapeutics Inc. (
PTCT )
175%
Rhythm Pharmaceuticals Inc. (
RYTM )
121%
Fate Therapeutics Inc. (
FATE )
112%
G1 Therapeutics Inc. (
GTHX )
91%
Apellis Pharmaceuticals Inc. (
APLS )
91%
Acorda Therapeutics Inc. (
ACOR )
79%
Cara Therapeutics Inc. (
CARA )
78%
UroGen Pharma Ltd. (
URGN )
77%
Viking Therapeutics Inc. (
VKTX )
75%
Akebia Therapeutics Inc. (
AKBA )
74%
AMAG Pharmaceuticals Inc. (
AMAG )
67%
Kura Oncology Inc. (
KURA )
66%
Flexion Therapeutics Inc. (
FLXN )
65%
GlycoMimetics Inc. (
GLYC )
60%
Corbus Pharmaceuticals Holdings Inc. (
CRBP )
60%
PDL BioPharma Inc. (
PDLI )
57%
Progenics Pharmaceuticals Inc. (
PGNX )
48%
Five Prime Therapeutics Inc. (
FPRX )
48%
Concert Pharmaceuticals Inc. (
CNCE )
41%
Voyager Therapeutics Inc. (
VYGR )
41%
CASI Pharmaceuticals Inc. (
CASI )
40%
Krystal Biotech Inc. (
KRYS )
39%
Achillion Pharmaceuticals Inc. (
ACHN )
38%
Aduro Biotech Inc. (
ADRO )
37%
Abeona Therapeutics Inc. (
ABEO )
37%
Albireo Pharma Inc. (
ALBO )
37%
Minerva Neurosciences Inc. (
NERV )
35%
Adamas Pharmaceuticals Inc. (
ADMS )
33%
Catalyst Pharmaceuticals Inc. (
CPRX )
33%
Kiniksa Pharmaceuticals Ltd. (
KNSA )
32%
Syros Pharmaceuticals Inc. (
SYRS )
27%
Arbutus Biopharma Corp. (
ABUS )
25%
Calithera Biosciences Inc. (
CALA )
24%
Xenon Pharmaceuticals Inc. (
XENE )
24%
State Street Institutional Treasury Plus Money Market Fund (
TPIXX )
3%
ALPS Medical Breakthroughs ETF (
SBIO )
0%
SBIO Dividends Annual Dividend Yield 2.37